Novavax (NASDAQ:NVAX) shares have soared premarket and are currently trading at $194, up 23.43% after yesterday’s close at $157.17 per share, but why?
Well, on Tuesday the company announced that its potential COVID-19 vaccine has generated a promising immune response in its early-stage clinical trials.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The company said that the phase one trial evaluated two doses of its Novavax vaccine in 131 healthy adults from the ages of 18-59 at two sites in Australia, with it being “well-tolerated” and having a “reassuring safety profile.”
The vaccine produced neutralising antibodies according to the company’s press release…
And, researchers believe these are key in building immunity to the virus.
They went on to say that the immune response was more robust than those who have recovered from the virus.
The Phase 1 data demonstrate that NVX-CoV2373 with our Matrix-M adjuvant is a well‑tolerated COVID-19 vaccine with a robust immunogenicity profile,” said Gregory M. Glenn, M.D., President, Research and Development at Novavax.
Source: TipRanks
So, what does that mean going forward?
Of course, there is still a long way to go…
Phase one trials aim to find the best doses for the drug with the fewest side effects…
And, with Novavax reporting that it had a reassuring safety profile, those are positive signs that it could now move on to the next stage.
But, there are still other stages to go through, with many companies further ahead, such as AstraZeneca and the University of Oxford who is conducting phase three trials.
So, while the signs are positive, it is best to stay cautious at this point. Remember most experts have commented that a vaccine won’t be available until at least 2021…
Although like you, I really hope its a lot sooner!
